Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23FN4O2 |
| Molecular Weight | 370.4206 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC#CC(=O)N[C@H]1CCCN(C1)C2=C3C(C)=C(C)NC3=C(C=C2F)C(N)=O
InChI
InChIKey=VJPPLCNBDLZIFG-ZDUSSCGKSA-N
InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1
| Molecular Formula | C20H23FN4O2 |
| Molecular Weight | 370.4206 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.6 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14.2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
66.6 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
179 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.9 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.8 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60.5 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16.3 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
97.2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.4 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.1 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
24.5 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
100 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
282 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.7 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.5 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
30.6 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
101 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.2 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
27.4 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
139 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.22 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg single, oral dose: 0.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.59 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.73 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.56 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.63 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.3 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.66 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.64 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.74 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.91 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.51 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.7 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/32198939/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BRANEBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.2% |
unknown |
BRANEBRUTINIB plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 20:53:17 GMT 2025
by
admin
on
Tue Apr 01 20:53:17 GMT 2025
|
| Record UNII |
7LBRZUYSHU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB15347
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
11026
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
121293929
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
C167033
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
7LBRZUYSHU
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
300000038099
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
FG-21
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY | |||
|
1912445-55-6
Created by
admin on Tue Apr 01 20:53:17 GMT 2025 , Edited by admin on Tue Apr 01 20:53:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
BINDER->LIGAND |
BINDING
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> NON-INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
REVERSIBLE
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |